Adc Therapeutics SA (NYSE: ADCT) on Monday, plunged -10.46% from the previous trading day, before settling in for the closing price of $2.39. Within the past 52 weeks, ADCT’s price has moved between $0.57 and $6.04.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 91.46%. The company achieved an average annual earnings per share of 42.06%. With a float of $77.83 million, this company’s outstanding shares have now reached $82.29 million.
Let’s determine the extent of company efficiency that accounts for 162 employees. In terms of profitability, gross margin is 89.36%, operating margin of -196.67%, and the pretax margin is -235.56%.
Adc Therapeutics SA (ADCT) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Adc Therapeutics SA is 19.50%, while institutional ownership is 55.29%. The most recent insider transaction that took place on Jul 01 ’24, was worth 1,124,000. In this transaction 10% Owner of this company bought 400,000 shares at a rate of $2.81, taking the stock ownership to the 15,669,217 shares. Before that another transaction happened on Jul 01 ’24, when Company’s 10% Owner bought 400,000 for $2.81, making the entire transaction worth $1,124,000. This insider now owns 12,995,040 shares in total.
Adc Therapeutics SA (ADCT) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 42.06% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.80% during the next five years compared to 84.52% growth over the previous five years of trading.
Adc Therapeutics SA (NYSE: ADCT) Trading Performance Indicators
Adc Therapeutics SA (ADCT) is currently performing well based on its current performance indicators. A quick ratio of 4.68 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.64.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.40, a number that is poised to hit -0.43 in the next quarter and is forecasted to reach -1.50 in one year’s time.
Technical Analysis of Adc Therapeutics SA (ADCT)
Looking closely at Adc Therapeutics SA (NYSE: ADCT), its last 5-days average volume was 0.54 million, which is a drop from its year-to-date volume of 0.63 million. As of the previous 9 days, the stock’s Stochastic %D was 4.76%. Additionally, its Average True Range was 0.23.
During the past 100 days, Adc Therapeutics SA’s (ADCT) raw stochastic average was set at 0.50%, which indicates a significant decrease from 0.85% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 78.60% in the past 14 days, which was lower than the 86.35% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.01, while its 200-day Moving Average is $3.64. However, in the short run, Adc Therapeutics SA’s stock first resistance to watch stands at $2.32. Second resistance stands at $2.49. The third major resistance level sits at $2.59. If the price goes on to break the first support level at $2.05, it is likely to go to the next support level at $1.95. Now, if the price goes above the second support level, the third support stands at $1.78.
Adc Therapeutics SA (NYSE: ADCT) Key Stats
Market capitalization of the company is 186.62 million based on 96,690K outstanding shares. Right now, sales total 69,560 K and income totals -240,050 K. The company made 18,460 K in profit during its latest quarter, and -43,970 K in sales during its previous quarter.
